Here's a summary of HIMS & HERS HEALTH, INC.'s (HIMS) financial performance based on their Q1 2025 10-Q filing:

Business Overview:

Hims & Hers Health, Inc. is a consumer-first platform transforming how customers fulfill their health and wellness needs. They offer access to a provider network, electronic medical records, digital prescriptions, and cloud-enabled pharmacy fulfillment. Their platform provides treatments for sexual health, mental health, dermatology, and weight loss.

Key Financial Highlights:

Revenue:

Q1 2025 revenue was $586.01 million, compared to $278.17 million in Q1 2024. This represents a significant increase in revenue year-over-year. Online revenue contributed $576.36 million, while wholesale revenue accounted for $9.65 million.

Profitability:

Gross profit for Q1 2025 was $430.69 million, compared to $229.10 million for Q1 2024.
Net income for Q1 2025 was $49.49 million, a substantial improvement from the $11.13 million net income in Q1 2024.

Expenses:

Marketing expenses were $231.24 million in Q1 2025, compared to $130.55 million in Q1 2024.
Operations and support expenses were $63.03 million in Q1 2025, compared to $38.75 million in Q1 2024.
Technology and development expenses were $29.91 million in Q1 2025, compared to $15.32 million in Q1 2024.
General and administrative expenses were $48.61 million in Q1 2025, compared to $34.57 million in Q1 2024.

Earnings Per Share (EPS):

Basic EPS for Q1 2025 was $0.22, compared to $0.05 in Q1 2024.
Diluted EPS for Q1 2025 was $0.20, compared to $0.05 in Q1 2024.

Share Count:

Weighted average shares outstanding (basic) for Q1 2025 were 221.99 million, compared to 213.45 million in Q1 2024.
Weighted average shares outstanding (diluted) for Q1 2025 were 246.61 million, compared to 229.36 million in Q1 2024.

Balance Sheet:

Cash and cash equivalents were $273.74 million as of March 31, 2025, compared to $220.58 million as of December 31, 2024.
Short-term investments were $48.94 million as of March 31, 2025, compared to $79.67 million as of December 31, 2024.
Total assets were $891.71 million as of March 31, 2025, compared to $707.54 million as of December 31, 2024.
Total liabilities were $342.45 million as of March 31, 2025, compared to $230.82 million as of December 31, 2024.
Stockholders' equity was $549.26 million as of March 31, 2025, compared to $476.72 million as of December 31, 2024.

Cash Flow:

Net cash provided by operating activities was $109.09 million for Q1 2025, compared to $25.84 million for Q1 2024.
Net cash used in investing activities was $32.80 million for Q1 2025, compared to net cash provided of $13.04 million for Q1 2024.
Net cash used in financing activities was $23.02 million for Q1 2025, compared to $30.31 million for Q1 2024.

Acquisitions:

In February 2025, HIMS acquired certain manufacturing assets from C S Bio Co. for approximately $39.1 million in cash and Class A common stock.
In February 2025, HIMS acquired Trybe Labs for $5.1 million in cash.
In September 2024, HIMS acquired MedisourceRx for $31.0 million in cash and Class A common stock.

Share Repurchase Program:

In July 2024, the Board of Directors authorized a share repurchase program for up to $100.0 million of the Companyâ€™s Class A common stock. As of March 31, 2025, $65.0 million remained available under the program.

Trading Arrangement:

Mike Chi, Chief Commercial Officer, adopted a Rule 10b5-1 trading arrangement on March 4, 2025, covering 825,264 securities.

Subsequent Events:

In April 2025, Apostrophe Pharmacy became a wholly-owned subsidiary of the Company.
In April 2025, the Company extended the lease term for one of its facilities, increasing the lease liability and corresponding ROU asset by $10.4 million.

Key Metrics:

Revenue Growth: The substantial year-over-year revenue growth indicates strong market demand and effective business strategies.
Profitability Improvement: The significant increase in net income suggests improved operational efficiency and cost management.
Cash Position: The increase in cash and cash equivalents indicates a healthy liquidity position.
Share Repurchase Program: The ongoing share repurchase program reflects management's confidence in the company's future prospects and commitment to returning value to shareholders.

Actionable Insights:

Continued Revenue Growth: HIMS has demonstrated strong revenue growth, indicating a successful business model and increasing market adoption. Investors should monitor the company's ability to sustain this growth trajectory.
Profitability Improvement: The significant increase in net income is a positive sign. Investors should assess whether this improvement is sustainable and driven by operational efficiencies or one-time gains.
Expense Management: While revenue is growing, expenses are also increasing. Investors should monitor the company's ability to manage expenses effectively to ensure profitability continues to improve.
Acquisitions: HIMS has been active in acquiring other companies. Investors should evaluate the strategic rationale and financial impact of these acquisitions.
Share Repurchase Program: The share repurchase program indicates management's confidence in the company's future prospects. Investors should monitor the program's progress and impact on shareholder value.
Trading Arrangement: The adoption of a Rule 10b5-1 trading arrangement by a key executive suggests a planned and orderly approach to selling shares. Investors should not view this as a negative signal, but rather as a routine practice.
Overall, HIMS's Q1 2025 results indicate a company with strong revenue growth, improving profitability, and a healthy balance sheet. However, investors should carefully monitor expense management, acquisition integration, and the impact of the share repurchase program to ensure the company's long-term success.
